文献速递其他结缔组织病自身炎症与 IgG4 相关病

静脉阿那白滞素治疗继发性HLH/MAS:细胞因子风暴的沉默策略

Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome.
PubMed 文献 · Lancet Rheumatol · 2020-05-04

本文为观点文章,阐述细胞因子风暴综合征(含sHLH/MAS)的管理挑战,并综述静脉阿那白滞素的药代动力学与安全性。作者报告其三中心12个月内46例sHLH/MAS患者中18例(39%)采用静脉给药,认为静脉阿那白滞素作为一线治疗的理由与安全性证据正在积累。

要点

  • 静脉阿那白滞素为超说明书用药,适用于需高剂量或皮下水肿、重度血小板减少、神经系统受累者
  • 三项国际三级中心12个月内46例sHLH/MAS患者中18例(39%)经静脉使用阿那白滞素
  • 重症患者皮下吸收不可靠且需多次注射以达到高剂量,故临床倾向静脉给药

核心结论

  • 静脉阿那白滞素作为sHLH/MAS一线治疗的理由与安全性证据正在积累,具重要临床相关性

研究设计与样本

  • 观点文章(Viewpoint),结合三项国际三级中心12个月内46例sHLH/MAS患者的用药经验并综述文献

主要发现

  • 46例sHLH/MAS患者中18例(39%)经静脉途径接受阿那白滞素治疗
  • 重症患者皮下吸收不可靠且需多次注射以达到所需高剂量
  • 高剂量需求、皮下水肿、重度血小板减少或神经系统受累时静脉给药具临床相关性

关键数值与推荐

  • 阿那白滞素获批皮下剂量为100 mg每日一次,用于类风湿关节炎、全身型幼年特发性关节炎、成人起病Still病及cryopyrin相关周期性综合征
  • 静脉给药用于sHLH/MAS属超说明书适应证与给药途径

临床怎么用

  • sHLH/MAS需高剂量阿那白滞素或存在皮下水肿、重度血小板减少、神经系统受累时可考虑静脉给药
  • 风湿科常在细胞因子风暴综合征管理中起主导作用,需跨专科协作

局限性

  • 静脉阿那白滞素用于sHLH/MAS为超说明书用药
  • 需建立国际多中心登记与生物样本库以更好理解病因发病机制并改善预后

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The term cytokine storm syndromes describes conditions characterised by a life-threatening, fulminant hypercytokinaemia with high mortality. Cytokine storm syndromes can be genetic or a secondary complication of autoimmune or autoinflammatory disorders, infections, and haematological malignancies. These syndromes represent a key area of interface between rheumatology and general medicine. Rheumatologists often lead in management, in view of their experience using intensive immunosuppressive regimens and managing cytokine storm syndromes in the context of rheumatic disorders or infection (known as secondary haemophagocytic lymphohistiocytosis or macrophage activation syndrome [sHLH/MAS]). Interleukin (IL)-1 is pivotal in hyperinflammation. Anakinra, a recombinant humanised IL-1 receptor antagonist, is licenced at a dose of 100 mg once daily by subcutaneous injection for rheumatoid arthritis, systemic juvenile idiopathic arthritis, adult-onset Still's disease, and cryopyrin-associated periodic syndromes. In cytokine storm syndromes, the subcutaneous route is often problematic, as absorption can be unreliable in patients with critical illness, and multiple injections are needed to achieve the high doses required. As a result, intravenous anakinra is used in clinical practice for sHLH/MAS, despite this being an off-licence indication and route of administration. Among 46 patients admitted to our three international, tertiary centres for sHLH/MAS and treated with anakinra over 12 months, the intravenous route of delivery was used in 18 (39%) patients. In this Viewpoint, we describe current challenges in the management of cytokine storm syndromes and review the pharmacokinetic and safety profile of intravenous anakinra. There is accumulating evidence to support the rationale for, and safety of, intravenous anakinra as a first-line treatment in patients with sHLH/MAS. Intravenous anakinra has important clinical relevance when high doses of drug are required or if patients have subcutaneous oedema, severe thrombocytopenia, or neurological involvement. Cross-speciality management and collaboration, with the generation of international, multi-centre registries and biobanks, are needed to better understand the aetiopathogenesis and improve the poor prognosis of cytokine storm syndromes.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Mehta P, Cron RQ, Hartwell J, et al. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2020. PMID: 32373790. doi:10.1016/S2665-9913(20)30096-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。